Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
UNKNOWN
Clinical Phase
NA
Total Enrollment
50 participants
Study Classification
INTERVENTIONAL
Study Start Date
2014-10-31
Study Completion Date
2016-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This research study is a randomized, controlled study developed to test how well a dry mouth product that contains xylitol affects some of the symptoms of gastroesophageal reflux disease (GERD. Individuals who experience symptoms of gastro esophageal reflux disease (GERD) and who are accepted into the study will be asked to report on the frequency and severity of several symptoms specific to the condition that occur during sleep. The study is composed of two phases:
Phase one involves collection of baseline information for two weeks. Phase two is the intervention phase of the study. In this phase of the study, each subject will be randomly assigned (like flipping a coin) to use either "the product" of interest or a different dry mouth product for two weeks.
Phase one involves collection of baseline information for two weeks. Phase two is the intervention phase of the study. In this phase of the study, each subject will be randomly assigned (like flipping a coin) to use either "the product" of interest or a different dry mouth product for two weeks.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Effect of Probiotic and Zinc Supplementation in Patients With Gastroesophageal Reflux Disease
NCT06664008
Gastro-oesophageal Reflux Disease
NOT_YET_RECRUITING
PHASE4
Impact of Timing on the Efficacy of Zegerid 40 mg in Healing Reflux Esophagitis: A Pilot Study
NCT00693225
Erosive Esophagitis
COMPLETED
PHASE4
Effect of Acid Reflux on Respiratory Physiology During Exercise in Athletes With GER-Response to Acid Suppression
NCT00444236
Exercise Triggered Asthma
Gastroesophageal Reflux
TERMINATED
PHASE1
Response to Supplement and Placebo in GERD
NCT01915173
Gastroesophageal Reflux Disease (GERD)
Heartburn
Dyspepsia
COMPLETED
NA
Efficacy and Speed of Action of a Product to Control Gastric Hydration and Gastroesophageal Reflux
NCT05060744
Oesophageal Reflux
Gastric Reflux
Hyperactivity; Stomach
UNKNOWN
NA
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The study is composed of two phases:
Phase one involves collection of baseline information for two weeks. Phase two is the intervention phase of the study. In this phase of the study, each subject will be randomly assigned (like flipping a coin) to use either "the product" of interest or a different dry mouth product for two weeks.
Phase 1
This first phase will involve having you report to the research coordinator through email the presence or absence of several symptoms associated with GERD that can occur during sleep. Phase 1 will occur over 14 days (and nights). You will also be asked to rate the relative severity of some of the symptoms. The information collected during this initial phase of the study will then be used to establish baseline values for the symptoms of interest and determine your eligibility for the intervention phase (phase 2) of the study.
Phase 2
In the second phase of the study, you will be given either enough gel or enough discs to use for 14 days (the duration of the second phase of the study). If you are given the gel, a small amount (specified in the directions) is to be applied to the mouth lining just before bed. If you are given the discs, one will be placed on the gums beside a molar in each cheek each night just before bed (specified in the directions). You will be asked to continue to provide daily email communication with the research coordinator detailing symptoms suggesting reflux experienced the prior night during product use as you did during phase 1 of the study.
During phases 1 and 2 of the study, you will be asked to continue taking any previously prescribed medication or over-the-counter preparations that you normally take for reflux and to maintain your regular dietary habits. However, you should not take any dry mouth remedy other than those supplied by the research coordinator just before bed.
Phase one involves collection of baseline information for two weeks. Phase two is the intervention phase of the study. In this phase of the study, each subject will be randomly assigned (like flipping a coin) to use either "the product" of interest or a different dry mouth product for two weeks.
Phase 1
This first phase will involve having you report to the research coordinator through email the presence or absence of several symptoms associated with GERD that can occur during sleep. Phase 1 will occur over 14 days (and nights). You will also be asked to rate the relative severity of some of the symptoms. The information collected during this initial phase of the study will then be used to establish baseline values for the symptoms of interest and determine your eligibility for the intervention phase (phase 2) of the study.
Phase 2
In the second phase of the study, you will be given either enough gel or enough discs to use for 14 days (the duration of the second phase of the study). If you are given the gel, a small amount (specified in the directions) is to be applied to the mouth lining just before bed. If you are given the discs, one will be placed on the gums beside a molar in each cheek each night just before bed (specified in the directions). You will be asked to continue to provide daily email communication with the research coordinator detailing symptoms suggesting reflux experienced the prior night during product use as you did during phase 1 of the study.
During phases 1 and 2 of the study, you will be asked to continue taking any previously prescribed medication or over-the-counter preparations that you normally take for reflux and to maintain your regular dietary habits. However, you should not take any dry mouth remedy other than those supplied by the research coordinator just before bed.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
GERD
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
SINGLE_GROUP
Primary Study Purpose
SUPPORTIVE_CARE
Blinding Strategy
DOUBLE
Participants
Investigators
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Data collection
This first phase will involve having you report to the research coordinator through email the presence or absence of several symptoms associated with GERD that can occur during sleep. Phase 1 will occur over 14 days (and nights).
Group Type
NO_INTERVENTION
No interventions assigned to this group
Intervention
In the second phase of the study, each subject will be given either a gel containing xylitol or discs containing xylitol to use for 14 days (the duration of the second phase of the study). If given the gel, a small amount (specified in the directions) is to be applied to the mouth lining just before bed. If given the discs, one will be placed on the gums beside a molar in each cheek each night just before bed (specified in the directions). Each subject will be asked to continue to provide daily email communication with the research coordinator detailing symptoms suggesting reflux experienced the prior night during product use as was provided during phase 1 of the study.
Group Type
ACTIVE_COMPARATOR
Xylitol
Intervention Type
DIETARY_SUPPLEMENT
A comparison between discs and gel
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Xylitol
A comparison between discs and gel
Intervention Type
DIETARY_SUPPLEMENT
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. A medical diagnosis of GERD
2. Awakening with a taste of refluxed stomach acid in the mouth
3. Heartburn during sleep
4. Voice hoarseness upon awakening
5. Antacid use at night
6. Dry mouth at bedtime or during the night
7. Experience difficulty chewing, swallowing, and speaking because of dry mouth
2. Awakening with a taste of refluxed stomach acid in the mouth
3. Heartburn during sleep
4. Voice hoarseness upon awakening
5. Antacid use at night
6. Dry mouth at bedtime or during the night
7. Experience difficulty chewing, swallowing, and speaking because of dry mouth
Exclusion Criteria
1. Under 18
2. Prior history of any of these conditions:
1. coronary artery disease
2. gallbladder disease
3. gastric or esophageal cancer
4. peptic ulcer disease
5. esophagitis, whether eosinophilic, infectious, or pill based
6. esophageal motility disorders
3. A history of thoracic, esophageal, or gastric surgery
4. No medical examination in the prior year
2. Prior history of any of these conditions:
1. coronary artery disease
2. gallbladder disease
3. gastric or esophageal cancer
4. peptic ulcer disease
5. esophagitis, whether eosinophilic, infectious, or pill based
6. esophageal motility disorders
3. A history of thoracic, esophageal, or gastric surgery
4. No medical examination in the prior year
Minimum Eligible Age
18 Years
Maximum Eligible Age
80 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Oral Care Research Associates, Seattle
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jeff Burgess DDS MSD
Research Coordinator
Responsibility Role
PRINCIPAL_INVESTIGATOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jeff A Burgess, DDS MSD
Role: STUDY_DIRECTOR
Oral Care Research Associates, Seattle
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
References
Explore related publications, articles, or registry entries linked to this study.
Holtmann G. Reflux disease: the disorder of the third millennium. Eur J Gastroenterol Hepatol. 2001 May;13 Suppl 1:S5-11.
Reference Type
BACKGROUND
Jung HK, Choung RS, Talley NJ. Gastroesophageal reflux disease and sleep disorders: evidence for a causal link and therapeutic implications. J Neurogastroenterol Motil. 2010 Jan;16(1):22-9. doi: 10.5056/jnm.2010.16.1.22. Epub 2010 Jan 31.
Reference Type
BACKGROUND
Ranjitkar S, Smales RJ, Kaidonis JA. Oral manifestations of gastroesophageal reflux disease. J Gastroenterol Hepatol. 2012 Jan;27(1):21-7. doi: 10.1111/j.1440-1746.2011.06945.x.
Reference Type
BACKGROUND
Bardhan KD, Strugala V, Dettmar PW. Reflux revisited: advancing the role of pepsin. Int J Otolaryngol. 2012;2012:646901. doi: 10.1155/2012/646901. Epub 2011 Nov 10.
Reference Type
BACKGROUND
Fass R, Pulliam G, Johnson C, Garewal HS, Sampliner RE. Symptom severity and oesophageal chemosensitivity to acid in older and young patients with gastro-oesophageal reflux. Age Ageing. 2000 Mar;29(2):125-30. doi: 10.1093/ageing/29.2.125.
Reference Type
BACKGROUND
Chait MM. Gastroesophageal reflux disease: Important considerations for the older patients. World J Gastrointest Endosc. 2010 Dec 16;2(12):388-96. doi: 10.4253/wjge.v2.i12.388.
Reference Type
BACKGROUND
Saritas Yuksel E, Vaezi MF. New developments in extraesophageal reflux disease. Gastroenterol Hepatol (N Y). 2012 Sep;8(9):590-9.
Reference Type
BACKGROUND
DeVault KR, Castell DO; American College of Gastroenterology. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol. 2005 Jan;100(1):190-200. doi: 10.1111/j.1572-0241.2005.41217.x.
Reference Type
BACKGROUND
Kahrilas PJ, Shaheen NJ, Vaezi MF, Hiltz SW, Black E, Modlin IM, Johnson SP, Allen J, Brill JV; American Gastroenterological Association. American Gastroenterological Association Medical Position Statement on the management of gastroesophageal reflux disease. Gastroenterology. 2008 Oct;135(4):1383-1391, 1391.e1-5. doi: 10.1053/j.gastro.2008.08.045. No abstract available.
Reference Type
BACKGROUND
Dolder M, Tutuian R. Laboratory based investigations for diagnosing gastroesophageal reflux disease. Best Pract Res Clin Gastroenterol. 2010 Dec;24(6):787-98. doi: 10.1016/j.bpg.2010.10.005.
Reference Type
BACKGROUND
Katz PO, Gerson LB, Vela MF. Guidelines for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol. 2013 Mar;108(3):308-28; quiz 329. doi: 10.1038/ajg.2012.444. Epub 2013 Feb 19. No abstract available.
Reference Type
BACKGROUND
Locke GR 3rd, Talley NJ, Fett SL, Zinsmeister AR, Melton LJ 3rd. Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology. 1997 May;112(5):1448-56. doi: 10.1016/s0016-5085(97)70025-8.
Reference Type
BACKGROUND
Fass R, Achem SR, Harding S, Mittal RK, Quigley E. Review article: supra-oesophageal manifestations of gastro-oesophageal reflux disease and the role of night-time gastro-oesophageal reflux. Aliment Pharmacol Ther. 2004 Dec;20 Suppl 9:26-38. doi: 10.1111/j.1365-2036.2004.02253.x.
Reference Type
BACKGROUND
Eckley CA, Rios Lda S, Rizzo LV. Salivary egf concentration in adults with reflux chronic laryngitis before and after treatment: preliminary results. Braz J Otorhinolaryngol. 2007 Mar-Apr;73(2):156-60. doi: 10.1016/s1808-8694(15)31060-0.
Reference Type
BACKGROUND
Guare RO, Ferreira MC, Leite MF, Rodrigues JA, Lussi A, Santos MT. Dental erosion and salivary flow rate in cerebral palsy individuals with gastroesophageal reflux. J Oral Pathol Med. 2012 May;41(5):367-71. doi: 10.1111/j.1600-0714.2011.01112.x. Epub 2011 Nov 14.
Reference Type
BACKGROUND
Wong WM, Lam KF, Cheng C, Hui WM, Xia HH, Lai KC, Hu WH, Huang JQ, Lam CL, Chan CK, Chan AO, Lam SK, Wong BC. Population based study of noncardiac chest pain in southern Chinese: prevalence, psychosocial factors and health care utilization. World J Gastroenterol. 2004 Mar 1;10(5):707-12. doi: 10.3748/wjg.v10.i5.707.
Reference Type
BACKGROUND
Jansson C, Nordenstedt H, Wallander MA, Johansson S, Johnsen R, Hveem K, Lagergren J. A population-based study showing an association between gastroesophageal reflux disease and sleep problems. Clin Gastroenterol Hepatol. 2009 Sep;7(9):960-5. doi: 10.1016/j.cgh.2009.03.007. Epub 2009 Mar 13.
Reference Type
BACKGROUND
Gisbert JP, Cooper A, Karagiannis D, Hatlebakk J, Agreus L, Jablonowski H, Zapardiel J. Impact of gastroesophageal reflux disease on patients' daily lives: a European observational study in the primary care setting. Health Qual Life Outcomes. 2009 Jul 2;7:60. doi: 10.1186/1477-7525-7-60.
Reference Type
BACKGROUND
Ferrus JA, Zapardiel J, Sobreviela E; SYMPATHY I study group. Management of gastroesophageal reflux disease in primary care settings in Spain: SYMPATHY I study. Eur J Gastroenterol Hepatol. 2009 Nov;21(11):1269-78. doi: 10.1097/MEG.0b013e32832a7d9b.
Reference Type
BACKGROUND
Gerson LB, Fass R. A systematic review of the definitions, prevalence, and response to treatment of nocturnal gastroesophageal reflux disease. Clin Gastroenterol Hepatol. 2009 Apr;7(4):372-8; quiz 367. doi: 10.1016/j.cgh.2008.11.021. Epub 2008 Dec 3.
Reference Type
BACKGROUND
Hungin AP, Hill C, Raghunath A. Systematic review: frequency and reasons for consultation for gastro-oesophageal reflux disease and dyspepsia. Aliment Pharmacol Ther. 2009 Aug 15;30(4):331-42. doi: 10.1111/j.1365-2036.2009.04047.x.
Reference Type
BACKGROUND
Wallander MA, Johansson S, Ruigomez A, Garcia Rodriguez LA, Jones R. Dyspepsia in general practice: incidence, risk factors, comorbidity and mortality. Fam Pract. 2007 Oct;24(5):403-11. doi: 10.1093/fampra/cmm050. Epub 2007 Aug 28.
Reference Type
BACKGROUND
Kusano M, Kouzu T, Kawano T, Ohara S. Nationwide epidemiological study on gastroesophageal reflux disease and sleep disorders in the Japanese population. J Gastroenterol. 2008;43(11):833-41. doi: 10.1007/s00535-008-2235-0. Epub 2008 Nov 18.
Reference Type
BACKGROUND
Fass R, Quan SF, O'Connor GT, Ervin A, Iber C. Predictors of heartburn during sleep in a large prospective cohort study. Chest. 2005 May;127(5):1658-66. doi: 10.1378/chest.127.5.1658.
Reference Type
BACKGROUND
Mody R, Bolge SC, Kannan H, Fass R. Effects of gastroesophageal reflux disease on sleep and outcomes. Clin Gastroenterol Hepatol. 2009 Sep;7(9):953-9. doi: 10.1016/j.cgh.2009.04.005. Epub 2009 Apr 16.
Reference Type
BACKGROUND
Marsicano JA, de Moura-Grec PG, Bonato RC, Sales-Peres Mde C, Sales-Peres A, Sales-Peres SH. Gastroesophageal reflux, dental erosion, and halitosis in epidemiological surveys: a systematic review. Eur J Gastroenterol Hepatol. 2013 Feb;25(2):135-41. doi: 10.1097/MEG.0b013e32835ae8f7.
Reference Type
BACKGROUND
Yoshikawa H, Furuta K, Ueno M, Egawa M, Yoshino A, Kondo S, Nariai Y, Ishibashi H, Kinoshita Y, Sekine J. Oral symptoms including dental erosion in gastroesophageal reflux disease are associated with decreased salivary flow volume and swallowing function. J Gastroenterol. 2012 Apr;47(4):412-20. doi: 10.1007/s00535-011-0515-6. Epub 2011 Dec 27.
Reference Type
BACKGROUND
Correa MC, Lerco MM, Cunha Mde L, Henry MA. Salivary parameters and teeth erosions in patients with gastroesophageal reflux disease. Arq Gastroenterol. 2012 Jul-Sep;49(3):214-8. doi: 10.1590/s0004-28032012000300009.
Reference Type
BACKGROUND
Fass R, Ofman JJ, Sampliner RE, Camargo L, Wendel C, Fennerty MB. The omeprazole test is as sensitive as 24-h oesophageal pH monitoring in diagnosing gastro-oesophageal reflux disease in symptomatic patients with erosive oesophagitis. Aliment Pharmacol Ther. 2000 Apr;14(4):389-96. doi: 10.1046/j.1365-2036.2000.00733.x.
Reference Type
BACKGROUND
Kao CH, Ho YJ, ChangLai SP, Liao KK. Evidence for decreased salivary function in patients with reflux esophagitis. Digestion. 1999;60(3):191-5. doi: 10.1159/000007658.
Reference Type
BACKGROUND
Helm JF, Dodds WJ, Hogan WJ. Salivary response to esophageal acid in normal subjects and patients with reflux esophagitis. Gastroenterology. 1987 Dec;93(6):1393-7. doi: 10.1016/0016-5085(87)90270-8.
Reference Type
BACKGROUND
Pope CE 2nd. Acid-reflux disorders. N Engl J Med. 1994 Sep 8;331(10):656-60. doi: 10.1056/NEJM199409083311007. No abstract available.
Reference Type
BACKGROUND
Smith DJ, Joshipura K, Kent R, Taubman MA. Effect of age on immunoglobulin content and volume of human labial gland saliva. J Dent Res. 1992 Dec;71(12):1891-4. doi: 10.1177/00220345920710120701.
Reference Type
BACKGROUND
Iorgulescu G. Saliva between normal and pathological. Important factors in determining systemic and oral health. J Med Life. 2009 Jul-Sep;2(3):303-7.
Reference Type
BACKGROUND
Helm JF, Dodds WJ, Hogan WJ, Soergel KH, Egide MS, Wood CM. Acid neutralizing capacity of human saliva. Gastroenterology. 1982 Jul;83(1 Pt 1):69-74. No abstract available.
Reference Type
BACKGROUND
http://www.moderndentistrymedia.com/jan_feb2012/walsh.pdf; Author: LJ Walsh; Title: Clinical aspects of salivary biology for the dental clinician. In ModerDentistryMedia
Reference Type
BACKGROUND
Dutta SK, Agrawal K, Mahmoud MA. Modulation of salivation and heartburn in response to the site of acid infusion in the human oesophagus. Aliment Pharmacol Ther. 2010 Sep;32(6):795-800. doi: 10.1111/j.1365-2036.2010.04397.x.
Reference Type
BACKGROUND
Haag S, Holtmann G. Onset of relief of symptoms of gastroesophageal reflux disease: post hoc analysis of two previously published studies comparing pantoprazole 20 mg once daily with nizatidine or ranitidine 150 mg twice daily. Clin Ther. 2010 Apr;32(4):678-90. doi: 10.1016/j.clinthera.2010.03.020.
Reference Type
BACKGROUND
Armstrong D, Pare P, Pericak D, Pyzyk M; Canadian Pantoprazole GERD Study Group. Symptom relief in gastroesophageal reflux disease: a randomized, controlled comparison of pantoprazole and nizatidine in a mixed patient population with erosive esophagitis or endoscopy-negative reflux disease. Am J Gastroenterol. 2001 Oct;96(10):2849-57. doi: 10.1111/j.1572-0241.2001.4237_a.x.
Reference Type
BACKGROUND
Vela MF. Medical treatments of GERD: the old and new. Gastroenterol Clin North Am. 2014 Mar;43(1):121-33. doi: 10.1016/j.gtc.2013.12.001. Epub 2013 Dec 31.
Reference Type
BACKGROUND
Burgess J, Lee P. XyliMelts time-release adhering discs for night-time oral dryness. Int J Dent Hyg. 2012 May;10(2):118-21. doi: 10.1111/j.1601-5037.2011.00532.x. Epub 2011 Oct 31.
Reference Type
BACKGROUND
Kerr AR, Corby PM, Shah SS, Epler M, Fisch GS, Norman RG. Use of a mucoadhesive disk for relief of dry mouth: a randomized, double-masked, controlled crossover study. J Am Dent Assoc. 2010 Oct;141(10):1250-6. doi: 10.14219/jada.archive.2010.0053.
Reference Type
BACKGROUND
Nwokediuko SC. Current trends in the management of gastroesophageal reflux disease: a review. ISRN Gastroenterol. 2012;2012:391631. doi: 10.5402/2012/391631. Epub 2012 Jul 11.
Reference Type
BACKGROUND
Helm JF, Dodds WJ, Pelc LR, Palmer DW, Hogan WJ, Teeter BC. Effect of esophageal emptying and saliva on clearance of acid from the esophagus. N Engl J Med. 1984 Feb 2;310(5):284-8. doi: 10.1056/NEJM198402023100503.
Reference Type
BACKGROUND
Printza A, Speletas M, Triaridis S, Wilson J. Is pepsin detected in the saliva of patients who experience pharyngeal reflux? Hippokratia. 2007 Jul;11(3):145-9.
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
1401
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
An Efficacy and Safety Study of XP19986 in Subjects With Symptomatic GERD
NCT00557401
COMPLETED
PHASE2
Sleep Disorders and Gastroesophageal Reflux Disease (GERD)
NCT00287391
COMPLETED
PHASE4
Which Supraesophageal Reflux Symptoms Reliably Respond to Proton-Pump-Inhibitor (PPI) Therapy
NCT00170001
COMPLETED
NA
Prevacid vs Lifestyle Modifications for the Treatment of LPR
NCT00274339
UNKNOWN
NA
Understanding the Pathophysiology and Effects of Diaphragmatic Breathing in Upright Gastroesophageal Reflux
NCT02972047
COMPLETED
NA
Effect of a Combination of Hyaluronic Acid, Chondroitin Sulphate and Magnesium Trisilicate on Subjects With GastroEsophageal Reflux Disease
NCT03883074
COMPLETED
NA
Compound Sodium Alginate Oral Suspension Sachet Symptomatic Relief Study
NCT02623062
COMPLETED
PHASE3
Sleep Position May Reduce Acid Reflux Symptoms at Night
NCT02320968
TERMINATED
NA
Hyaluronic Acid in Patients With Gastroesophageal Reflux Disease
NCT05561179
UNKNOWN
NA
Compound Sodium Alginate Oral Suspension Sachet 4-hour Esophageal pH Study in GERD Patients
NCT02619747
TERMINATED
PHASE3
Effects of Diet on Reflux and Dyspepsia
NCT02425553
COMPLETED
Standardized Dysphagia Diet in Clinical Evaluation of Swallowing Function
NCT05634980
UNKNOWN
The Effects of Dexlansoprazole for the Treatment of Throat-Related Reflux
NCT01317472
TERMINATED
NA
Selective 5-HT4 Receptor Agonist and Proton Pump Inhibitor (PPI) in Subjects With Gastroesophageal Reflux Disease (GERD)
NCT01472939
COMPLETED
PHASE2
Breathing Exercises in Patients With Gastroesophageal Reflux
NCT06812650
COMPLETED
NA
Gracie Diet for Gastroesophageal Reflux Disease
NCT04360252
ACTIVE_NOT_RECRUITING
NA
Clinical Investigation to Assess the Acid Neutralisation Activity of a Calcite Chewing Gum
NCT05129670
COMPLETED
NA
The Influence of Hypnotic Medications on Sleep Arousal and Its Effect on Gastroesophageal Reflux
NCT00462137
COMPLETED
What is the Predictive Value of the Reflux Impact Scale
NCT00536328
TERMINATED
SThe Effects of Melatonin on GERD Symptoms
NCT00564590
UNKNOWN
PHASE1/PHASE2
Gastroesophageal Reflux Disease (GERD)/Nighttime Heartburn and Driving Performance
NCT01079884
COMPLETED
NA
Nexium Capsules S-CEI for Justification of Esomeprazole in Acid Related Disease for Reflux Symptom Healing Based on Patient Clinical Outcomes
NCT02477475
COMPLETED
A Post-market Registry to Assess Safety and Performance of RefluxStop™ in the Treatment of GERD in General Hospital Practice
NCT07004439
NOT_YET_RECRUITING
NA
Local Phase IV, Gastroesophageal Reflux Disease (GERD) Sleep Study US
NCT00660660
COMPLETED
PHASE4
Mechanisms Preventing Pharyngeal Reflux
NCT05696184
RECRUITING
NA